EndoClot Plus
EndoClot Plus is a Santa Clara-based medical device company that develops patented polysaccharide and adhesive hemostatic products for gastrointestinal endoscopy, commercialized exclusively through Olympus in the US and EMEA.
- Company typePrivate
- Founded2011
- HeadquartersSanta Clara, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What EndoClot Plus does
EndoClot Plus is a privately held medical device company headquartered in Santa Clara, California, that develops and manufactures hemostatic products for use during gastrointestinal (GI) endoscopic procedures. The company was founded around 2011 and operates manufacturing operations in Suzhou, China, established in 2014. It employs between 11 and 50 people across both sites. Its commercial focus is on controlling GI bleeding through a portfolio of single-use, endoscopic-application products.
The company's product portfolio is built on two proprietary, patented polymer platforms — AMP® (Absorbable Modified Polymer) and AHP (Adhesive Hemostatic Polymer) — both protected in the United States and Europe. The cleared and marked product set includes EndoClot Adhesive (CE marked May 2018), EndoClot SIS (FDA cleared January 2020), and EndoClot PHS / Polysaccharide Hemostatic System (FDA cleared February 2021). Together these address different hemostatic use cases within endoscopic practice, ranging from adhesive fixation to sprayable powder-based bleeding control.
EndoClot Plus monetizes through sales of its hemostatic devices to hospitals and endoscopy centers, executed almost exclusively through Olympus Corporation under an exclusive US distribution agreement signed in April 2022 and an exclusive EMEA agreement signed in December 2022. The company has disclosed limited financing history, with a single named round featuring Ming Bioventures in October 2018. Pricing model, contract structure, and revenue figures are not publicly disclosed.
EndoClot Plus firmographics
Firmographics- Name
- EndoClot Plus
- Legal name
- EndoClot Plus, Inc.
- Website
- https://endoclot.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- EndoClot Plus is a Santa Clara-based medical device company that develops patented polysaccharide and adhesive hemostatic products for gastrointestinal endoscopy, commercialized exclusively through Olympus in the US and EMEA.
- Ownership category
- akta.pro rank
EndoClot Plus industry classification
Industry- Product category
- Gastrointestinal Hemostatic Medical Devices
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)
- akta.pro secondary industry
- Advanced Endoscopy (ERCP/EUS/Interventional) (HLAKAEAC)
Keywords
Where EndoClot Plus is headquartered
LocationHeadquarters
- HQ city
- Santa Clara
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
EndoClot Plus business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Medical Device Sales: Sale of single-use medical devices including EndoClot® PHS, EndoClot® Adhesive, and EndoClot® SIS. Products are sold through exclusive distribution partnership with Olympus Corporation. Revenue is generated from product sales to healthcare providers performing gastrointestinal endoscopic procedures.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
EndoClot Plus product offering
Product offeringCore offering
EndoClot Plus develops and manufactures single-use medical devices for gastrointestinal endoscopy, including the EndoClot® Polysaccharide Hemostatic System (PHS) using proprietary AMP® polymer technology, the EndoClot® Adhesive using AHP technology, and the EndoClot® Submucosal Injection System (SIS). These products are used by endoscopists and GI surgeons to control bleeding in the upper and lower GI tract and to provide submucosal lift prior to lesion excision.
Product overview
EndoClot Plus is a medical device company offering a portfolio of hemostatic and submucosal injection products for gastrointestinal endoscopy. The core product line consists of the EndoClot® Polysaccharide Hemostatic System (PHS) using AMP® technology, the EndoClot® Adhesive using AHP technology, and the EndoClot® Submucosal Injection System (SIS) for lesion lift procedures. These products are supported by specialized delivery systems including endoscopic powder and gel delivery systems. The company operates through distribution partnerships with Olympus in the U.S. and EMEA regions.
Differentiator
Problem solved
Functional benefit
Brands
- EndoClot PHS: EndoClot Polysaccharide Hemostatic System - single use medical device consisting of Absorbable Modified Polymers (AMP) and powder delivery system for controlling bleeding in GI tract
- EndoClot Adhesive
- EndoClot SIS
- AMP Technology
- AHP Technology
Products and services
- EndoClot® Polysaccharide Hemostatic System (EndoClot® PHS) A single-use medical device consisting of Absorbable Modified Polymers (AMP®) and a powder delivery system (applicator) used by gastroenterologists and endoscopists to control bleeding in the upper and lower gastrointestinal tract during endoscopy. Effective for ulcer bleeding, tumor bleeding, EMR/ESD procedures, and prevention of re-bleeding.
- EndoClot® Adhesive A single-use medical device consisting of Adhesive Hemostatic Polymer (AHP) particles and an applicator for accurate delivery to GI tract lesions. Forms a gelled adhesive matrix that seals and protects wound sites for several hours to several days. Used by endoscopists for GI hemostasis.
- EndoClot® Submucosal Injection System (EndoClot® SIS) A single-use medical device composed of AMP® derived from plant starch for submucosal lift during GI endoscopic procedures prior to excision of polyps, adenomas, and early stage cancers. FDA cleared and CE marked for sale in the USA, EU, UK, Australia and other countries.
- EndoClot® Air Compressor An external gas source that provides regulated pressure to propel AMP® powder through the delivery catheter of the EndoClot® Powder Delivery System during endoscopic procedures.
Quantifiable outcome
- EndoClot® PHS is FDA cleared and CE marked for sale in USA, EMEA and selective AP countries
- +1 more outcomes
Companies that use EndoClot Plus
Customer profileSegments1 record
Ideal customer profiles1 record
EndoClot Plus technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
EndoClot Plus partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Olympus CorporationflagshipIn May 2023, Olympus extended its partnership with EndoClot Plus to introduce hemostatic agents supporting safer gastrointestinal procedures. This extension builds on the exclusive distribution agreements established for U.S. (April 2022) and EMEA (December 2022) markets, further strengthening the collaboration between the two companies in the GI endoscopy space.
- Olympus CorporationflagshipOlympus Corporation announced an exclusive U.S. distribution agreement with EndoClot Plus, Inc. in April 2022. This agreement gave Olympus exclusive rights to distribute EndoClot's hemostatic products in the United States market. In December 2022, this partnership was expanded to include the EMEA (Europe, Middle East, Africa) region. Orders for U.S. and EMEA customers are placed through local Olympus representatives.
- Olympus CorporationcoreOlympus partnered with EndoClot Plus in April 2022 to improve accessibility of hemostasis products during ERCP (Endoscopic Retrograde Cholangiopancreatography) procedures. The partnership leverages Olympus's established distribution network to make EndoClot's hemostatic products more widely available to healthcare providers performing ERCP procedures globally.
Scale indicators2 records
Recent moves7 records
Expansion highlights4 records
EndoClot Plus competitors and assessment
Company assessmentBroad incumbents
- Ethicon (Johnson & Johnson): Ethicon markets surgical hemostatic agents and energy devices used in GI surgery and endoscopy; it competes with EndoClot in bleeding management, particularly for procedures that cross the endoscopy-surgery boundary.
- Medtronic: Medtronic's GI Solutions franchise (acquired from Covidien) competes in endoscopic hemostasis and energy-based resection; it overlaps with EndoClot at the multi-modality hemostasis level, albeit with a far broader portfolio.
- Boston Scientific: Boston Scientific offers the Resolution 360 hemostatic clip family and a broad GI endoscopy franchise; it overlaps with EndoClot in the same hospital accounts but competes with a wider, multi-modality hemostasis portfolio.
- HOYA (Pentax Medical): Pentax Medical (HOYA) manufactures GI endoscopes and therapeutic accessories; it overlaps with EndoClot in the same endoscopic procedure workflows and competes for hospital procedure-room spend.
- Olympus Corporation: Olympus is both EndoClot's exclusive global distributor and a manufacturer of competing GI hemostatic and therapeutic devices; the relationship is partnership-plus-overlap, and Olympus's portfolio breadth and scope installed base dwarf EndoClot's standalone footprint.
Direct peers
- Conmed: Conmed markets hemostatic products and GI endoscopy accessories; it overlaps with EndoClot in bleeding management and therapeutic endoscopy, addressing similar hospital customers.
- Cook Medical: Cook Medical markets HemoSpray and a portfolio of GI endoscopic hemostatic devices that directly compete with EndoClot PHS for bleeding-control cases; both companies serve the same gastroenterology customers with powder/powder-equivalent hemostats.
- ERBE Elektromedizin: ERBE supplies VIO electrosurgical and endoscopic hemostasis systems used in GI endoscopy; it competes with EndoClot for the same therapeutic endoscopy budgets and brings deep clinical evidence in advanced GI procedures.
Emerging players
- STERIS: STERIS's GI endoscopy product line (built through the Cantel acquisition) competes in endoscopic accessories and infection prevention; it overlaps with EndoClot in hospital GI departments and offers multi-product bundles to similar buyers.
- Micro-Tech Endoscopy: Micro-Tech Endoscopy is a China-based GI endoscopy accessories company offering hemostatic and resection devices at price-competitive terms; it competes with EndoClot especially in APAC markets and benefits from a similar Chinese supply-chain footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
EndoClot Plus social profiles
Digital presenceEndoClot Plus compliance and trust
Trust signalCompliance6 records
EndoClot Plus financial estimates
Financial estimateRevenue estimate
Valuation estimate
EndoClot Plus leadership team
Management profileNumber of profiles
EndoClot Plus subsidiaries and ownership
Company hierarchySubsidiaries1 record
EndoClot Plus funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EndoClot Plus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EndoClot Plus
What does EndoClot Plus do?
EndoClot Plus develops and manufactures single-use medical devices for gastrointestinal endoscopy, including the EndoClot® Polysaccharide Hemostatic System (PHS) using proprietary AMP® polymer technology, the EndoClot® Adhesive using AHP technology, and the EndoClot® Submucosal Injection System (SIS). These products are used by endoscopists and GI surgeons to control bleeding in the upper and lower GI tract and to provide submucosal lift prior to lesion excision.
Is EndoClot Plus a public or private company?
EndoClot Plus is a private company. It is classified as venture growth investor backed and is currently operating.
When was EndoClot Plus founded?
EndoClot Plus was founded in 2011. It employs 11 to 50 people.
Where is EndoClot Plus based?
EndoClot Plus is headquartered in Santa Clara, United States, in the North America region.
How does EndoClot Plus make money?
One revenue line is on record: medical Device Sales.
Who are EndoClot Plus's main competitors?
Broad incumbents on record are Ethicon (Johnson & Johnson), Medtronic, Boston Scientific, HOYA (Pentax Medical) and Olympus Corporation. Direct peers are Conmed, Cook Medical and ERBE Elektromedizin. Emerging players are STERIS and Micro-Tech Endoscopy.
Does EndoClot Plus have an API?
No public API is recorded for EndoClot Plus.
What industry is EndoClot Plus in?
EndoClot Plus's product category is Gastrointestinal Hemostatic Medical Devices. Its primary akta.pro industry code is HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools), with a secondary code of HLAKAEAC, Advanced Endoscopy (ERCP/EUS/Interventional). Its SIC code is 3841.